Abstract
Introduction: Durable antitumor activity has been observed with cemiplimab and pembrolizumab in advanced metastatic cSCC. The randomized, double-blind, phase 3 KEYNOTE-630 study (NCT03833167) will evaluate adjuvant pembrolizumab in resectable, high-risk, LA cSCC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
